Mitomycin C and 5-fluorouracil as second choice treatment in advanced breast cancer patients.
Twenty-six patients with advanced breast cancer, (12 previously treated with adriamycin-containing regimens, 14 not exposed to adriamycin because of poor cardiac performance), were treated with combination chemotherapy including mitomycin C plus 5-fluorouracil. Objective response was seen in 7/66 patients (26.9%) with a statistically higher response rate in patients with fewer than 2 metastatic sites. Because of mild toxicity this regimen can be safely used as second-line chemotherapy for heavily pretreated patients and as first-line treatment in patients with poor cardiac performance.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects
D008937:Mitomycins; D016685:Mitomycin; D005472:Fluorouracil